NEW YORK, March 12, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Biogen Idec Inc. (NASDAQ: BIIB), Johnson & Johnson (NYSE: JNJ),
Express Scripts Inc. (NASDAQ: ESRX), Merck & Co. Inc. (NYSE:
MRK), and Forest Laboratories Inc. (NYSE: FRX). Private wealth
members receive these notes ahead of publication. To reserve
complementary membership, limited openings are available at:
http://www.AnalystsReview.com/register
Biogen Idec Inc. Analyst Notes
On March 5, 2014, Biogen Idec Inc.
(Biogen) announced that it has entered into collaboration with
Eisai Co. Ltd (Eisai) to develop and commercialize two of Eisai's
clinical candidates for Alzheimer's disease (AD), E2609 and
BAN2401. Further, the agreement provides Eisai with an option to
jointly develop and commercialize two of Biogen's candidates for
AD, the anti-amyloid beta (Aβ) antibody BIIB037 and an anti-tau
monoclonal antibody.The Company informed that it will provide Eisai
with an upfront payment and a fixed amount of development, approval
and commercial milestone payments. Furthermore, the agreement also
includes options for Eisai to receive an additional one-time
payment from Biogen related to joint development and
commercialization activities in Japan. "This collaboration is a natural fit
with our mission to develop therapies for patients with severe
neurodegenerative diseases. Eisai's candidates have demonstrated
compelling early data and complement our AD research while
extending our pipeline in this critical area," said George A. Scangos, Ph.D., CEO of Biogen. The
full analyst notes on Biogen Idec Inc. are available to download
free of charge at:
http://www.AnalystsReview.com/03122014/BIIB/report.pdf
Johnson & Johnson Analyst
Notes
On March 6, 2014, Janssen-Cilag
International NV (Janssen), a Johnson & Johnson company,
announced that it has been granted conditional approval for SIRTURO
(bedaquiline) by the European Commission (EC) in the European
Union. The approval is for use of SIRTURO as part of an appropriate
combination regimen for pulmonary multi-drug resistant tuberculosis
(MDR-TB) in adult patients, when an effective treatment regimen
cannot otherwise be composed for reasons of resistance or
tolerability. "We are delighted that SIRTURO® has been approved for
use in the European Union, as it represents a significant step
forward in helping address a very serious global public health
issue," said Wim Parys, Head
R&D, Global Public Health at Janssen. The decision from the EC
follows a positive opinion from the Committee for Medicinal
Products for Human Use (CHMP) of the European Medicines Agency
(EMA) recommending the approval of bedaquiline on December 20, 2013. The full analyst notes on
Johnson & Johnson are available to download free of charge
at:
http://www.AnalystsReview.com/03122014/JNJ/report.pdf
Express Scripts Inc. Analyst Notes
On February 27, 2014, Express
Scripts Inc. (Express Scripts) announced the launch of a new
Physician-Dispensed Medication Solution to provide workers'
compensation payers visibility into their true total pharmacy costs
and help reduce costs resulting from physician dispensing of
medications. "When drugs are repackaged for physician-dispensing,
the price is significantly inflated and those costs get passed on
to the payers," said Jennifer
Kaburick, Vice President, Workers' Compensation Product
Management & Strategic Initiatives. "Processing bills for
physician-dispensed medications through our enhanced adjudication
system helps payers reduce costs, while staying compliant with
state workers' compensation laws that address physician
dispensing." The Company informed that the new solution is
completely customizable based on the state jurisdiction. The full
analyst notes on Express Scripts Inc. are available to download
free of charge at:
http://www.AnalystsReview.com/03122014/ESRX/report.pdf
Merck & Co. Inc. Analyst Notes
On March 4, 2014, Merck & Co.
Inc. (Merck) announced results from a Phase 2b study evaluating two
doses of its investigational house dust mite sublingual
immunotherapy tablet (MK-8237). Both doses of MK-8237 (at
once-daily doses of 6 Development Units and 12 Development units)
produced a significant dose- and time-dependent reduction in
average TNSS over the last four hours of the chamber challenge at
week 24 of treatment compared to placebo, the primary efficacy
endpoint of the study. A Phase 3 study of MK-8237 in adolescents
and adults with house dust mite-induced allergic rhinitis is
currently screening patients. "We look forward to continuing with
Phase 3 research, which will provide further insight into the
safety and efficacy of MK-8237," said Dr. Sean Curtis, Vice President, Respiratory and
Immunology, Merck Research Laboratories. The full analyst notes on
Merck & Co. Inc. are available to download free of charge
at:
http://www.AnalystsReview.com/03122014/MRK/report.pdf
Forest Laboratories Inc. Analyst
Notes
On March 4, 2014, Forest
Laboratories, Inc. (Forest) and Adamas Pharmaceuticals Inc.,
announced Forest's submission of a New Drug Application (NDA) to
the Food and Drug Administration for a fixed-dose combination (FDC)
of memantineHCl extended release (ER) and donepezil HCl for the
treatment of moderate to severe dementia of the Alzheimer's type.
"The concurrent use of memantine and donepezil is a
well-established treatment option for patients with moderate to
severe dementia related to Alzheimer's disease. Using the two drugs
together appears to provide benefit over using acetylcholinesterase
inhibitors alone. Reducing the number of pills by offering patients
a fixed-dose combination helps lessen the daily medication burden
and could improve patient adherence and compliance," said
Pierre Tariot, MD, at the Banner
Alzheimer's Institute. The full analyst notes on Forest
Laboratories Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03122014/FRX/report.pdf
About Analysts Review
We provide our members with a simple and reliable way to
leverage our economy of scale. Most investors do not have time to
track all publicly traded companies, much less perform an in-depth
review and analysis of the complexities contained in each
situation. That's where Analysts Review comes in. We provide a
single unified platform for investors' to hear about what matters.
Situation alerts, moving events, and upcoming opportunities.
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
http://www.AnalystsReview.com
SOURCE Analysts Review